Physiologic Regulation of FGF-23
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00356512|
Recruitment Status : Completed
First Posted : July 26, 2006
Last Update Posted : July 2, 2017
This study will explore the regulation of fibroblast growth factor-23 (FGF-23). It is a hormone recently identified as a regulator of the blood levels of phosphorus and vitamin D, both of which are essential for overall health and especially important for bone health. The parathyroid hormone (PTH) regulates phosphorus and calcium, but people with hypoparathyroidism or pseudohypoparathyroidism do not have sufficient PTH action. There are genetic diseases that influence FGF-23, causing abnormal metabolism of phosphorus and vitamin D, thus affecting the bones. Also, there are rare tumors that may cause overproduction of FGF-23 causing debilitating bone disease.
Patients ages 18 and older who have low PTH levels, or are resistant to PTH action, and take calcitriol and calcium supplements, who are not pregnant, and who do not have kidney disorders may be eligible for this study. During the 4-day study, patients will be provided with a controlled diet that has a lower than usual phosphorus content. On day 1, patients will be admitted to the NIH Clinic Center and undergo blood and urine tests to measure calcium, phosphorus, vitamin D, and FGF-23. They will continue with their regular medicine for hypoparathyroidism. On that day and throughout the study, patients will fast from 10:00 p.m. to 8:00 a.m. the following day. On day 2, patients will continue fasting until 4:00 p.m. A tube will be placed in the vein of each arm: one for drawing blood and the other for infusing calcium. Just one intravenous (IV) line will be used on the other days. Patients will receive calcium chloride for 8 hours, at a dose carefully monitored by a machine. The purpose is to bring the blood calcium level to the high normal range or just above. Blood and urine samples will be collected periodically, to check for effects of calcium chloride on FGF-23 and PTH. On days 3 and 4, patients will not take calcitriol and calcium but will receive injections of PTH, under the skin, two times each day. On day 3, blood and urine samples will be again be collected for analysis. On day 4, patients will receive one dose of calcitriol by IV. The total amount of blood drawn during this study will be about 5 ounces.
|Condition or disease|
Vitamin D and phosphate are central to normal mineral homeostasis and important in many physiologic functions including skeletal integrity. For several decades parathyroid hormone (PTH) has been recognized as a central regulator of serum vitamin D and phosphate levels. Recently, FGF-23 has been identified as central in the regulation of the metabolism of vitamin D and serum phosphorus. The organ primarily responsible for the physiologic production of FGF-23 appears to be the skeleton. The study of FGF-23 metabolism and its direct effect on mineral metabolism is confounded by the classic endocrine feedback loops that exist among serum calcium, phosphorus, 1,25-(OH)2-vitamin D (1,25-D), and PTH. It is possible that any of these (phosphorus, calcium, 1,25-D, and/or PTH) are important in the regulation of serum FGF-23. The goal of this study is to identify what factors regulate serum FGF-23.
To overcome the confounding effect of PTH, we will study patients deficient in PTH (hypoparathyroidism) or resistant to PTH at the kidney (pseudohypoparathyroidism type 1B, PHP1B). The kidney is one of the primary organs responsible for regulating serum phosphorus and generating 1,25-D. It is the target of PTH and FGF-23. While patients with PHP1B are resistant to the action of PTH at the kidney, they are sensitive to the action of PTH at the bone, the tissue that produces FGF-23. Physiologic manipulation of the serum phosphorus, 1,25-D, calcium, and PTH in subjects with hypoparathyroidism or PHP1B will allow for a nearly complete dissection of the factors that are potential regulators of serum FGF-23.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Physiologic Regulation of FGF-23|
|Study Start Date :||July 19, 2006|
|Primary Completion Date :||September 2, 2009|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00356512
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|